Related references
Note: Only part of the references are listed.Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study
Nobuyuki Miyasaka et al.
Modern Rheumatology (2014)
Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective
Fabien B. Vincent et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation
Pauline A. van Schouwenburg et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
ADALIMUMAB TROUGH LEVEL IN BLOOD CORRESPONDING WITH CLINICAL RESPONSE
M. F. Pouw et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
A Test-based Strategy Is More Cost Effective Than Empiric Dose Escalation for Patients With Crohn's Disease Who Lose Responsiveness to Infliximab
Fernando S. Velayos et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2013)
Therapeutic drug monitoring of biologics for inflammatory bowel disease
Jean-Frederic Colombel et al.
INFLAMMATORY BOWEL DISEASES (2012)
Assessing Response and Loss of Response to Biological Therapies in IBD
Henit Yanai et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept
Anna Jamnitski et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials
David T. Felson et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Is There a Need for Immunopharmacologic Guidance of Anti-Tumor Necrosis Factor Therapies?
Klaus Bendtzen
ARTHRITIS AND RHEUMATISM (2011)
Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up
Geertje M. Bartelds et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis
Dora Pascual-Salcedo et al.
RHEUMATOLOGY (2011)
Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
Waqqas Afif et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study
G. M. Bartelds et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Frequency and Effectiveness of Dose Increase of Adalimumab, Etanercept, and Infliximab in Daily Clinical Practice
M. Blom et al.
ARTHRITIS CARE & RESEARCH (2010)
Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis
T. R. D. J. Radstake et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy
K. Pavelka et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Certolizumab Pegol Plus Methotrexate Is Significantly More Effective Than Placebo Plus Methotrexate in Active Rheumatoid Arthritis Findings of a Fifty-Two-Week, Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study
Edward Keystone et al.
ARTHRITIS AND RHEUMATISM (2008)
Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate
Jonathan Kay et al.
ARTHRITIS AND RHEUMATISM (2008)
Willingness to Accept versus Willingness to Pay in a Discrete Choice Experiment
Janneke P. C. Grutters et al.
VALUE IN HEALTH (2008)
WTP and WTA: Do people think differently?
David K. Whynes et al.
SOCIAL SCIENCE & MEDICINE (2007)
Productivity costs among patients with rheumatoid arthritis: the influence of methods and sources to value loss of productivity
SMM Verstappen et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Determinants of direct costs in Dutch rheumatoid arthritis patients
SMM Verstappen et al.
ANNALS OF THE RHEUMATIC DISEASES (2004)
Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate - The ARMADA trial
ME Weinblatt et al.
ARTHRITIS AND RHEUMATISM (2003)
Share Paper
